Placenta Accreta Spectrum, Present and Future: The Eunice Kennedy Shriver National Institute of Child Health and

Christina M Duzyj1, Brett D Einerson, Yalda Afshar

  • 1Department of Obstetrics and Gynecology, Massachusetts General Hospital, the Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, the Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Brigham and Women's Hospital and Harvard Medical School, and the Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; the Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah; the Division of Maternal-Fetal Medicine, University of California, Los Angeles, and the Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, the Department of Obstetrics and Gynecology, Stanford School of Medicine, Stanford, the Department of Radiology, University of California, San Diego, La Jolla, and the National Accreta Foundation, Saratoga, California; the Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, the Department of Obstetrics and Gynecology, UT Southwestern Medical Center, Dallas, the Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at UTHealth Houston, and the Department of Women's Health, the University of Texas at Austin, Dell Medical School, Austin, Texas; the Department of Obstetrics & Gynecology, Inova Fairfax, Fairfax, the Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, and the Department of Obstetrics and Gynecology, Comprehensive Cancer Center, University of Virginia Health, Charlottesville, Virginia; the Department of Obstetrics & Gynaecology, University of Toronto, and the Division of Maternal-Fetal Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada; the Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France; the Department of Obstetrics and Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland; the Department of Obstetrics and Gynecology, Columbia University, New York, New York; and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.

PubMed

Insights

Experts convened to address challenges in diagnosing and managing placenta accreta spectrum (PAS) disorder. The workshop identified knowledge gaps and outlined strategies for future research and improved patient care in PAS.

Area of Science:

  • Maternal-Fetal Medicine
  • Obstetrics and Gynecology
  • Medical Research Infrastructure

Background:

  • Placenta accreta spectrum (PAS) presents significant maternal health risks due to complex diagnosis and management.
  • Effective screening, diagnosis, and treatment strategies for PAS are crucial for improving patient outcomes.

Purpose of the Study:

  • To identify knowledge gaps in placenta accreta spectrum (PAS) disorder.
  • To inform future research and best practices for PAS screening, diagnosis, and management.
  • To enhance collaboration among healthcare professionals, researchers, and patient advocates.

Main Methods:

  • Convened a workshop on June 10-11, 2024, hosted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
  • Brought together multidisciplinary experts, including healthcare professionals, researchers, stakeholders, and patient advocates.
  • Facilitated discussions on resources, infrastructure, collaboration, and patient experiences.

Main Results:

  • Identified critical knowledge gaps in the screening, diagnosis, and management of PAS.
  • Explored strategies for optimizing research resources and strengthening partnerships.
  • Highlighted the importance of patient perspectives in guiding future research and care.

Conclusions:

  • The workshop fostered consensus on essential PAS topics and identified clinical and research priorities.
  • Emphasized the need for enhanced collaboration and infrastructure to advance PAS care.
  • Recognized patient experiences as vital for improving outcomes in placenta accreta spectrum disorder.